Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

BACKGROUND: The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies. METHODS: M2698 was administered as monotherapy (escalation, 15–380 mg daily; food effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsimberidou, Apostolia-Maria, Shaw, Jamie V., Juric, Dejan, Verschraegen, Claire, Weise, Amy M., Sarantopoulos, John, Lopes, Gilberto, Nemunaitis, John, Mita, Monica, Park, Haeseong, Ellers-Lenz, Barbara, Tian, Hui, Xiong, Wenyuan, Kaleta, Remigiusz, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371902/
https://www.ncbi.nlm.nih.gov/pubmed/34407844
http://dx.doi.org/10.1186/s13045-021-01132-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371902/
https://www.ncbi.nlm.nih.gov/pubmed/34407844
http://dx.doi.org/10.1186/s13045-021-01132-z

Ejemplares similares